Viridian Therapeutics, Inc.\DEVRDN

Viridian Therapeutics finally has a product to sell: Lumvoa (veligrotug-vvze), an FDA-approved subcutaneous therapy for thyroid eye disease (TED) that the company says showed ‘rapid, consistent, and durable reductions’ of key signs in two phase-3 trials. The press release calls it the first approved treatment for both active and chronic TED, which sounds like a milestone until you remember the company spent the last several years burning cash while waiting for this single label. The launch is live, but the filings don’t yet show how many vials left the warehouse in June or July. (source: Viridian Therapeutics press release, https://www.viridiantherapeutics.com/press-release/viridian-therapeutics-announces-u-s-fda-approval-and-launch-of-lumvoa-veligrotug-vvze-for-the-treatment-of-thyroid-eye-disease/)

The company’s website still talks about ‘engineering potential best-in-class medicines’, a phrase that in biotech doubles as a disclaimer and a prayer. Viridian’s pipeline page lists multiple candidates ‘in clinical studies for TED’, but the only concrete number in the latest filings is the $350 million the company raised in June via concurrent public offerings of convertible notes and common stock-$350 million that arrived just in time to offset the $119.7 million of operating cash used in the quarter ending March 31, 2026. (source: Viridian Therapeutics newsroom and 10-Q, period ending 2026-03-31, https://www.viridiantherapeutics.com/newsroom/)

The balance sheet tells the real story: $789 million of assets against $153 million of liabilities, leaving $636 million of equity that feels less like a fortress and more like a spreadsheet held together with parentheses. Net income attributable to the parent was a $104.9 million loss, operating income was a $116.2 million loss, and the only capital expenditure tallied in the quarter was $23,000-cheap office chairs, perhaps, but not the kind of capex that builds a bioreactor. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1590750/000119312526294547/xslF345X06/ownership.xml)

If you want a chart, the SEC filings are the only legitimate source here: start with the company facts JSON on EDGAR and work backwards. The renderer will place approved images; the prose stays focused on what the filings actually contain. (source: SEC EDGAR company facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001590750.json)

The June $350 million raise arrived with a convertible-note coupon of 1.75% due 2032, which means the company is paying bond investors less than it is paying its own cash burn. The ‘upsized’ offering language in the press release is classic biotech theatre: the market took the shares, the cash arrived, and the burn clock kept ticking. The filings do not yet show a single revenue line for Lumvoa, so the cash inflow is matched by a cash outflow that hasn’t yet turned into sales. (source: Viridian Therapeutics press release, https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211dex991.htm)

What changed this week? Nothing in the filings changes the equation: the company still has no revenue line, still has a quarterly cash burn north of $100 million, and still has a balance sheet that looks like a ledger designed by someone who really likes parentheses. The only new evidence is the launch of Lumvoa, which is a product milestone, not a financial one. The tension sits between the polished platform story and the plain numbers: $350 million raised, $119.7 million burned, and no revenue yet booked. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1590750/00011931252629452/xslF345X06/ownership.xml)